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Protein refoldingAlphaA-crystallin is a molecular chaperone; it prevents aggregation of denaturing proteins. We have
previously demonstrated that upon modiﬁcation by a metabolic α-dicarbonyl compound, methylglyoxal
(MGO), αA-crystallin becomes a better chaperone. AlphaA-crystallin also assists in refolding of denatured
proteins. Here, we have investigated the effect of mild modiﬁcation of αA-crystallin by MGO (with 20–
500 µM) on the chaperone function and its ability to refold denatured proteins. Under the conditions used,
mildly modiﬁed protein contained mostly hydroimidazolone modiﬁcations. The modiﬁed protein exhibited
an increase in chaperone function against thermal aggregation of βL- and γ-crystallins, citrate synthase (CS),
malate dehydrogenase (MDH) and lactate dehydrogenase (LDH) and chemical aggregation of insulin. The
ability of the protein to assist in refolding of chemically denatured βL- and γ-crystallins, MDH and LDH, and
to prevent thermal inactivation of CS were unchanged after mild modiﬁcation by MGO. Prior binding of
catalytically inactive, thermally denatured MDH or the hydrophobic probe, 2-p-toluidonaphthalene-6-
sulfonate (TNS) abolished the ability of αA-crystallin to assist in the refolding of denatured MDH. However,
MGO modiﬁcation of chaperone-null TNS-bound αA-crystallin resulted in partial regain of the chaperone
function. Taken together, these results demonstrate that: 1) hydroimidazolone modiﬁcations are sufﬁcient to
enhance the chaperone function of αA-crystallin but such modiﬁcations do not change its ability to assist in
refolding of denatured proteins, 2) the sites on the αA-crystallin responsible for the chaperone function and
refolding are the same in the native αA-crystallin and 3) additional hydrophobic sites exposed upon MGO
modiﬁcation, which are responsible for the enhanced chaperone function, do not enhance αA-crystallin's
ability to refold denatured proteins.ithiothreitol; GdHCl, guanidine
dehydrogenase; LDH, lactate
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The mammalian eye lens is a vital organ responsible for the
transmission of light for proper vision. Crystallins are the dominant
structural proteins within the lens, comprising up to 90% of total
proteins. Crystallins are of three types: α-, β- and γ-crystallins, which
interact among themselves to maintain transparency [1]. Alpha-
crystallin is a major protein in the lens, constituting 40% of total
proteins. It consists of two subunits, αA- and αB-crystallins, whichexist in a molar ratio of 3:1 and form polydisperse oligomers of ∼40
subunits with an average molecular mass of ∼800 kDa [2]. Alpha-
crystallin belongs to the sHsp (small heat shock protein) family,whose
structural and functional characteristics are conserved frombacteria to
humans [3,4]. Unlike the classical chaperones, sHsp prevent the
aggregation and precipitation of a variety of unrelated proteins [5].
Like other members of the sHsp family, α-crystallin functions as a
molecular chaperone. It prevents aggregation of partially denatured
proteins [6]. The oligomeric state of the protein appears to be
necessary for this function, but this hypothesis is controversial [7,8].
Support for this role has come from many studies in which client
proteins are subjected to denaturing by high temperature or
chemicals, in the presence or absence of α-crystallin. It is now
apparent that all three domains of α-crystallin, the N-terminus, the
crystallin domain and the C-terminus, are important for the chaperone
function [5]. Hydrophobic patches within these domains appear to
bind to client proteins during the chaperone function. However, short
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also function as chaperones [9], implying that the whole protein may
not be necessary for the chaperone function.
Much support for a role forα-crystallin's chaperone function in the
lens has come from genetically modiﬁed animals and from studies on
human hereditary cataracts. Targeted disruption of αA- or αB-
crystallin, or both together, resulted in serious developmental defects
or cataract formation in mice [10,11]. Several point mutations in α-
crystallin that have been identiﬁed as responsible for human cataracts
cause either total or partial loss of chaperone function [12–14].
Furthermore, overexpression of mutant forms of humanαA-crystallin
that have diminished chaperone function leads to cataract formation
in mice [14,15]. These observations strongly suggest that the
chaperone function of α-crystallin is necessary for the lens to remain
transparent throughout life.
However, like other proteins, α-crystallin also undergoes post-
translational modiﬁcation in the lens, such as, oxidation, truncation
and glycation [16,17]. Such modiﬁcations tend to accumulate in the
lens because of its negligible protein turnover. These modiﬁcations, in
general, have negative consequences on chaperone function. How-
ever, one type of modiﬁcation appears to have a beneﬁcial effect on
chaperone function and is by the reaction of a metabolic dicarbonyl
compound, methylglyoxal (MGO).
MGO is produced non-enzymatically from sugar fragmentation
reactions and decomposition of triose phosphate intermediates during
glycolysis, and also during catabolism of threonine and acetone [18].
MGO reactswith arginine and lysine residues on crystallins to produce
stable adducts on them. Several such adducts are present in the human
lens. They are carboxyethyllysine (CEL) [19], methylglyoxal lysine
dimer (MOLD) [20], methylglyoxal-derived imidazoline crosslink
(MODIC) [21], hydroimidazolones [22] and argpyrimidine [23].
While MOLD is a lysine–lysine cross linking structure, MODIC is a
lysine–arginine crosslinking structure. CEL is a lysinemodiﬁcation and
hydroimidazolones and argpyrimidine are arginine modiﬁcations
(Fig. 1). Studies have shown that several of these products accumulate
in aging lens proteins [19–22].
We and others have previously shown that MGO modiﬁcation of
αA-crystallin enhances its chaperone function [24,25]. We then
showed that it was the modiﬁcation of speciﬁc arginine residues to
argpyrimidine that led to enhanced chaperone function [25].
Replacement of two of such arginine residues with alanine by site-
directedmutagenesis also led to enhanced chaperone function [26]. In
addition, conversion of lysine to arginine-like structures followed by
MGO modiﬁcation led to enhanced chaperone function as well [27].
Previous reports showed that mild modiﬁcation with MGO (500 µM)
leads to mostly hydroimidazolone modiﬁcations in proteins [28,29].
Thus, it was possible that the enhancement of chaperone function in
MGO-modiﬁed αA-crystallin occurred from hydroimidazolone mod-
iﬁcations, in addition to argpyrimidine.Fig. 1.MGOmodiﬁcations in proteins. MGO reacts with arginine residues in proteins to form
chaperone function of human αA-crystallin.Alpha-crystallin performs another potentially signiﬁcant function:
it assists in refolding denatured proteins [30,31]. In this study we have
investigated the relationship between hydroimidazolone modiﬁca-
tions and the chaperone function, and assessed the impact of such
modiﬁcations on the protein refolding ability of MGO-modiﬁed αA-
crystallin.2. Materials and methods
2.1. Chemicals
Dithiothreitol (DTT), guanidine hydrochloride(GdHCl), bovine
serum albumin, bovine insulin, malate dehydrogenase (MDH), lactate
dehydrogenase (LDH), citrate synthase (CS), oxaloacetic acid, acetyl
CoA, ethylene diamine tetraacetic acid disodium salt dihydrate
(EDTA), 5,5′-Dithiobis 2-nitro-benzoic acid (DTNB), methylglyoxal
(MGO), iodoacetamide (IAA), and chymotrypsin were obtained from
Sigma Chemical Co., St. Louis, MO. 2-(p-toluidinyl)naphthalene-6-
sulfonate (TNS) was obtained from Molecular Probes (Invitrogen,
Carlsbad, CA). Centrifugal ﬁlters (100 kDa cutoff) were obtained from
Millipore (Bedford, MA). All other chemicals were analytical grade.
MGO was puriﬁed by low pressure distillation [25].2.2. Protein puriﬁcation
Human recombinant αA-crystallin was puriﬁed as reported in our
previous paper [26]. Human lenses (from a 19 year old donor) were
homogenized in 2.0 ml of 50 mM sodium phosphate buffer, pH 7.4
containing 100 mM NaCl, 1 mM EDTA and 100 µM PMSF and
centrifuged at 10,000 g at 4 °C for 30 min. The soluble proteins in the
supernatant were fractionated on a Sephacryl S-300 gel ﬁltration
column (1.5×100 cm) at 4 °C. The fractions corresponding to βL- and
γ-crystallins were pooled and dialyzed against water and lyophilized.2.3. Modiﬁcation of αA-crystallin by MGO
AlphaA-crystallin (5 mg/ml) in 0.1 M phosphate buffer pH 7.4 was
incubated with puriﬁed MGO (20, 50, 100 and 500 µM) at 37 °C in the
dark under sterile conditions for 2 days. After 2 days, unbound MGO
was removed by dialysis against 50 mM phosphate buffer (pH 7.4)
and protein concentration was determined by the Bradford assay
(Bio-Rad, Hercules, CA) using BSA as the standard. Since these
incubations used much lower concentrations of MGO and shorter
incubation period than the previous studies [24,25,32], the modiﬁed
proteins in the present study are henceforth referred to as ‘mildly
modiﬁed αA-crystallin’. AlphaA-crystallin incubated in the absence of
MGO served as the control.hydroimidazolone and argpyrimidine adducts. Formation of these adducts improves the
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Mildly modiﬁed αA-crystallin was mixed with 6 N HCl and
incubated for 16 h at 110 °C. The acid was evaporated in a Savant
SpeedVac system and the residue was suspended in 250 µl of water
ﬁltered through a 0.45 µm centrifugal ﬁlter. Aliquots of all samples
were separated by HPLC to measure argpyrimidine. The HPLC con-
ditions were set up according to Wilker et al. [23].
2.5. Identiﬁcation of hydroimidazolone in mildly modiﬁed α-crystallin
AlphaA-crystallinmodiﬁedwith 0, 20, 50, 100, or 500 µMMGOwas
subjected to SDS-PAGE under denaturing condition on a 12% gel. The
Coomassie stained protein band corresponding to αA-crystallin was
excised from the gel and digested by trypsin and subjected to mass
spectrometry as described previously [27]. Brieﬂy, protein bands are
cut from the gel,minced and subjected to in-gel digestionwith trypsin.
Analysis of proteolytic peptidewas performed using a LTQOrbiTrapXL
linear ion trapmass spectrometer (Thermo Fisher Scientiﬁc, Walthaw,
MA) coupled with an Ultimate 3000 HPLC system (Dionex, Sunnyvale,
CA). The spectra were acquired by data-dependent methods, consist-
ing of a full scan andMS/MS on the ﬁve most abundant precursor ions
at the collision energy of 30%. The obtained data were submitted for a
database search using Mascot (Matrix Science, Boston, MA) by setting
hydroimidazolone and argpyrimidine modiﬁcations on arginine.
2.6. Puriﬁcation of
Nδ-(5-Methyl-4-oxo-5-hydroimidazolone-2-yl)-L-ornithine
2.6.1. MGH1
MGH1 was isolated from the incubation mixture of MGO (220 µl,
1.4 mmol) and L-arginine (213 mg, 1.2 mmol) in 10 ml phosphate
buffer (0.2 M, pH 7.4). The reactionmixture was incubated for 4.5 h at
40 °C. Subsequently, the pH was adjusted to 4.0 with 1 N HCl. A
sample (8 ml) of the solution was adjusted to pH 1.0 with 1 N HCl and
subjected to ion exchange chromatography on a Dowex® 50Wx4 4-
400 column (2.5 cm i.d.×22 cm, H+-form). Before being conditioned
with pyridinium formate (0.2 M, pH 5.0), the column was washed
with 1 M NaOH, 1 M HCl, and water. Fractions were collected and
analyzed by thin-layer chromatography (TLC). TLC was performed on
silica gel 60 F254 plates (Merck) using n-butanol/H2O/HOAc/pyridine
4:2:3:3 as the mobile phase. Visualization of separated material was
achieved with ninhydrin. Fractions with material having Rf=0.48
were pooled and subjected to preparative HPLC as follows.
A Besta HD 2-200 pump (Wilhelmsfeld, Germany) with a Gynkotek
ﬂuorescence detector RF-530 and a SERVOGOR 220 pen recorder was
used. Chromatographic separations were performed on a stainless steel
column (VYDAC 218TP1022, 250×25 mm, RP18, 10 µm) using a ﬂow
rate of 15 ml/min. The mobile phase used was water (solvent A) and
MeOH/water (7:3 v/v; solvent B). To both solvents A and B, 1.2 ml/
l heptaﬂuorobutyric acid (HFBA) was added. Samples were injected at
5% B and run isocratically. Fractionswithmaterial eluting at tR=62 min
having a Rf=0.48 on TLCwere collected, combined, and freeze-dried to
yield a colorless amorphic residue (49.22 mg, 11.6%, MGH1×2 HFBA).
The chemical structure of the product was conﬁrmed as MGH1 by 1H-,
13C-NMR and high resolution mass spectrometry, which was fully
compatiblewithpreviously publisheddata [33]. Accuratemass (meanof
three measurements±standard deviation) was determined: m/z
229.1314±0.0007 [M+H]+ (229.1312, calculated for C9H17N4O3).
2.7. Quantiﬁcation of hydroimidazolone in mildly modiﬁed α-crystallin
by liquid chromatography and mass spectrometry
MGO-modiﬁed proteins (1.2 mg in each case) were enzymatically
hydrolyzed as previously described [34] and analyzed by LC/MS. The
HPLC apparatus (Jasco, Groß-Umstadt, Germany) consisted of a pump(PU-2080 Plus) with degasser (LG-2080-02) and quaternary gradient
mixer (LG-2080-04), a column oven (Jasco Jetstream II) and an
Autosampler (AS-2057 Plus). Chromatographic separations were
performed on a stainless steel column packed with RP-18 material
(VYDAC CRT, no. 218TP54, 250×4.0 mm, RP 18, 5 µm, Hesperia, CA)
using a ﬂow rate of 1.0 ml/min. The mobile phase used was water
(solvent A) and MeOH/water (7:3 (v/v), solvent B). To both solvents
(A and B), 1.2 ml/l heptaﬂuorobutyric acid (HFBA) was added.
Analysis was performed at 25 °C column temperature using isocratic
elution at 95%A/5%B.Mass spectrometric detectionwas conducted on
a API 4000 Q Trap LC/MS/MS system (Applied Biosystems/MDS Sciex,
Concord, ON, Canada) equipped with a turbo ionspray source using
electrospray ionisation in positive mode: sprayer capillary voltage
4.0 kV, nebulizing gas ﬂow 50 ml/min, heating gas 60 ml/min at
550 °C and curtain gas 40 ml/min. The multiple reaction monitoring
(MRM) mode was used, utilizing collision-induced dissociation (CID)
of the protonatedmolecules with compound speciﬁc oriﬁce potentials
and fragment speciﬁc collision energies. MGH1 (m/z 229.2→70.1,
114.1, 116.1) was detected at RT=36.5 min. Quantiﬁcation was
performed using the standard addition method using the authentic
reference compound of MGH1, which was synthesized as above.
2.8. UV-circular dichroism spectrometry
The conformational changes of αA-crystallin (unmodiﬁed and
mildly modiﬁed) were observed by recording far-UV and near-UV CD
spectra at 25 °C in a Jasco 810 spectropolarimeter (Jasco, Inc., Japan).
The far-UV spectra were recorded between 195 and 250 nm in a 1 mm
path length CD quartz cell, at a scan speed of 20 nm/min. The
concentration of protein was 0.2 mg/ml in 10 mM sodium phosphate
buffer pH 7.4. The near-UV CDwas recorded between 250 and 350 nm
in a 10 mm path length CD quartz cell, at a scan speed of 20 nm/min.
The protein concentrationwas 1 mg/ml in the same phosphate buffer.
2.9. TNS-ﬂuorescence
The surface hydrophobicity of native and MGO-modiﬁed αA-
crystallinwas studiedwith TNS, a hydrophobic probe. AlphaA-Crystallin
(0.1 mg/ml) in 50 mM phosphate buffer (pH 7.4) was incubated with
100 µM TNS for 2 h at 25 °C. Fluorescence emission spectra were
recorded between 350 and 520 nm using an excitation wavelength of
320 nm. The excitation and emission slit widths were each 5 nm.
2.10. Analysis of chaperone function of mildly modiﬁed α-crystallin
The chaperone function of MGO-modiﬁed and unmodiﬁed αA-
crystallin was evaluated using six client proteins: human βL-crystallin,
human γ-crystallin, malate dehydrogenase (MDH) lactate dehydro-
genase (LDH), CS and insulin. CS and insulin chaperone assays were
performed in 96-microwell plates using a micro plate reader
(SpectraMax, Model 190; Molecular Devices, Sunnyvale, CA). The
total reaction volume was 250 µl. Human βL-crystallin, human γ-
crystallin, MDH and LDH chaperone assays were performed in a DU
800 spectrophotometer, using quartz cuvettes with 1 cm pathlengths.
The total reaction volume was 500 µl. The following assays were
performed to evaluate chaperone function.
2.10.1. βL-Crystallin aggregation assay
βL-Crystallin (0.25 mg/ml) was incubated with native or MGO-
modiﬁedαA-crystallin (0.00625 mg/ml) at 60 °C in 50 mMphosphate
buffer pH 7.4 and light scattering was monitored at 360 nm in the
kinetic mode. βL-Crystallin without αA-crystallin served as control.
2.10.2. γ-Crystallin aggregation assay
γ-Crystallin (0.125 mg/ml) was incubated with native or MGO-
modiﬁedαA-crystallin (0.00625 mg/ml) at 65 °C in 50 mMphosphate
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kinetic mode. γ-Crystallin without αA-crystallin served as control.
2.10.3. CS aggregation assay
Citrate synthase (CS) was dialyzed against 40 mM HEPES buffer,
pH 7.4 for 24 h. CS (0.06 mg/ml) in 40 mM HEPES buffer, pH 7.4) was
incubated with native and MGO-modiﬁed αA-crystallin (0.004 mg/
ml) at 43 °C and light scattering was monitored at 360 nm [35]. CS
without αA-crystallin served as control.
2.10.4. MDH aggregation assay
MDH was dialyzed against 50 mM phosphate buffer (pH 7.4) for
24 h. MDH (0.25 mg/ml) and incubated with native and mildly
modiﬁed αA-crystallin (0.25 mg/ml) in 50 mM phosphate buffer (pH
7.4) at 50 °C and light scattering was monitored at 360 nm. [36] MDH
incubated in the absence of αA-crystallin served as the control.
2.10.5. LDH aggregation assay
LDH was dialyzed against 50 mM phosphate buffer (pH 6.7) for
24 h. LDH (0.25 mg/ml) was incubated with native and mildly
modiﬁed αA-crystallin (0.0125 mg/ml) in 50 mM phosphate buffer
(pH 6.7) at 60 °C and light scattering was monitored at 360 nm in the
kinetic mode. LDH incubated in the absence of αA-crystallin served as
the control.
2.10.6. Insulin aggregation assay
Insulin (0.32 mg/ml) in 50 mM phosphate buffer (pH 7.2) was
incubated at 25 °C with native and MGO-modiﬁed αA-crystallin
(0.064 mg/ml). Insulin without αA-crystallin served as control.
Insulin aggregation was initiated by adding freshly prepared DTT to
a ﬁnal concentration of 20 mM, and light scattering at 400 nm was
monitored for 1 h in the kinetic mode [37].
2.11. Preparation of αA-crystallin–MDH and αA-crystallin–TNS
complexes
MDH (1 mg/ml) was incubated with 500 µM of iodoacetamide in
50 mM phosphate buffer (pH 7.4) for 1 h, in the absence of light, at
room temperature. Excess iodoacetamide was removed by dialysis for
24 h at 4 °C against 50 mM phosphate buffer (pH 7.4). MDH activity
was measured as described previously [26], and was found to be
completely abolished by iodoacetamide treatment. The catalytically
inactiveMDH (1 mg/ml)was incubatedwithαA-crystallin (2 mg/ml)
at 50 °C for 1 h in 50 mM sodium phosphate buffer, pH 7.4. The
complex was centrifuged at 10,000 g for 30 min at 4 °C. The clear
supernatant was loaded on to Sephacryl S-300 gel ﬁltration column
and elutedwith 50 mMphosphate buffer (pH 7.4) containing 100 mM
NaCl. The αA-crystallin–MDH complex was collected, pooled and
concentrated using a 10KCentriconﬁlter (Millipore, Billerica,MA). The
concentration of αA-crystallin in the complex was determined by an
ELISA using an anti-αA-crystallin monoclonal antibody (see below).
AlphaA-crystallin (5 mg/ml) was incubated with 2.5 mM TNS in
50 mM phosphate buffer (pH 7.4) for 2 h at room temperature. The
complex was extensively dialyzed (48 h) against 0.1 M phosphate
buffer (pH 7.4) to remove excess TNS. TheαA-crystallin–TNS complex
(5 mg/ml) was incubated with or without 500 µM MGO for 2 days in
0.1 M phosphate buffer (pH 7.4) under sterile conditions, in the dark.
ExcessMGOwas removed by dialysis against 50 mMphosphate buffer
(pH 7.4). The concentration of αA-crystallin in the αA-crystallin–TNS
and MGO-modiﬁed αA-crystallin–TNS complexes was determined by
the Bradford assay, using BSA as the standard.
2.12. ELISA for αA-crystallin
Microplate wells were coated overnight with 0.125, 0.25, 0.5, 1 or
2 µg of human recombinant αA-crystallin per well in 50 mMcarbonate buffer (pH 9.6), in triplicate. The wells were then washed
three times with PBS-T and incubated with 50 µl of rabbit anti-αA/
αB-crystallin polyclonal antibody (1:500) (Assay Designs, Ann Arbor,
MI) for 1 h at 37 °C. Following this step, the wells were washed three
times with PBS-T, and incubated for 1 h at 37 °C with 50 µl of goat
anti-rabbit antibody (Sigma Aldrich, St. Louis, MO) diluted in PBS-T
(1:5000). After the wells were washed with PBS-T, they were
incubated with 100 µl of 3, 3′, 5, 5′-tetramethylbenzidine substrate
(Sigma). The enzyme reaction was stopped by the addition of 50 µl of
2 N H2SO4, and the absorbance was measured at 450 nm in a Dynex
MRX 5000 Microplate Reader. A standard curve for αA-crystallin was
generated from the values obtained from recombinant αA-crystallin
and from this the concentration of αA-crystallin in the αA-crystallin–
MDH complex was determined.
2.13. Thermal inactivation of citrate synthase in the presence of
αA-crystallin
Citrate synthase was dialyzed overnight against 40 mM HEPES
buffer (pH 7.4). CS (15 µM) was diluted 100-fold in 40 mM HEPES
buffer pH 7.4 (ﬁnal volume 300 µl), in the presence or absence of
30 µM αA-crystallin. The inactivation reaction was started by placing
the mixture in a water bath set at 43 °C. At regular time intervals,
aliquots were withdrawn and stored on ice. The residual CS activity
was measured according to the procedure of Zhi et al [38]. Brieﬂy,
the reaction mixture consisted of 50 mM Tris–HCl buffer pH 8.0
containing 2 mM EDTA, 100 µM oxaloacetic acid, 100 µM DTNB and
150 µM of acetyl CoA. The activity assay was performed at 25 °C and
the increase in absorbance at 412 nm was recorded. CS (15 µM)
diluted 100-fold into 40 mM HEPES buffer (pH 7.4) and kept on ice
served as the control.
2.14. Protein refolding assay
The ability of αA-crystallin to assist in the refolding of denatured
proteins was measured, using human βL-crystallin, human γ-crystallin,
MDH and LDH as client proteins.
The unfolding and rapid refolding of crystallinswas done according
to previously published procedure [39]. βL- and γ-crystallins (300 µg
each) were denatured in 20 mM sodium phosphate buffer (pH 7.4)
containing 8 M urea in the presence of 60 µg of native or MGO-
modiﬁed αA-crystallin for 5 h at room temperature. Rapid refolding
was done by diluting 50 µl of incubated samples with 950 µl of 10 mM
phosphate buffer (pH 7.4) containing 100 mM NaCl. The mixture was
incubated for 1 h at room temperature and turbidity was measured at
360 nm in a Beckman DU-600 spectrophotometer. The percentage
recovery ofβL and γ-crystallinswas calculated according to previously
published procedure [39].
MDH (1 µM) was denatured in 6 M GdHCl for 8 h at 25 °C.
Refolding was initiated by diluting the denatured MDH 100-fold in a
refolding buffer (pH 7.5) containing 50 mM phosphate, 10 mM
magnesium acetate, and 5 mM DTT, with or without 30 µM αA-
crystallin (native and mildly modiﬁed), αA-crystallin–MDH complex,
αA-crystallin–TNS complex and MGO-modiﬁed αA-crystallin–TNS
complex. The enzyme concentration was 10 nM during refolding. The
activity of refolded enzyme was assayed by adding 20 µl of refolding
mixture at various time intervals to 480 µl of a refolding buffer that
contained 0.1 mM NADH and 0.4 mM oxaloacetate. The decrease in
absorbance at 340 nm with time was recorded. MDH (1 µM) kept on
ice served as the control.
LDH (1 µM)was denatured in 6 MGdHCl for 8 h at 25 °C. Refolding
was performed as described for the MDH assay, with the exception
that 0.4 mM of sodium pyruvate was used as the substrate and the
assay was performed at 37 °C. The concentration of αA-crystallin
(native and MGO-modiﬁed) was 30 µM. LDH (1 µM) kept on ice
served as control. Similar refolding assays were performed with BSA
Table 2
Quantiﬁcation of hydroimidazolone (MGH1) in MGO-modiﬁed αA-crystallin.
MGO added (µM) MGH1 (nmol)/mg protein
20 1.37
50 3.04
100 7.59
500 27.80
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effects.
3. Results and discussion
In our previous study, we showed that MGO modiﬁcation of αA-
crystallin enhances its chaperone function [25]. In that study we used
high concentrations of MGO (up to 5 mM). Another study that
reported improvement in the chaperone function also used similar
high concentrations of MGO [24]. The aim of this study was to
determine whether the improvement in chaperone occurred at low
concentrations of MGO and to identifyMGOmodiﬁcations responsible
for such a change. Another aim was to determine if modiﬁcation by
low concentrations of MGO would adversely affect αA-crystallin's
ability to refold denatured proteins, as previously reported with high
concentrations of MGO [24].
3.1. Hydroimidazolones are the major modiﬁcations of MGO in
αA-crystallin
LC/MS–MSspectrometrywasused todetect and identify siteswhere
MGO had modiﬁed αA-crystallin. As shown in Table 1, at 20 µM MGO
out of the 13 arginine residues inαA-crystallin, 4were alreadymodiﬁed
to hydroimidazolone (R12, R65, R157 and R163). Hydroimidazolone
modiﬁcation occurredonother arginine residues as the concentration of
MGO increased. With 500 µM MGO, we observed hydroimidazolone
modiﬁcation on 11 arginine residues. Argpyrimidine was not detected
(by HPLC) in any of the samples (data not shown). The formation of
hydroimidazolone at low concentrations of MGO has been observed as
the predominant modiﬁcation in other proteins as well [29,40]. We
previously reported thatmodiﬁcation of R21 and R103 to argpyrimidine
in αA-crystallin made it a better chaperone [25]. In that study, we used
high concentrations of MGO to modify αA-crystallin that resulted in
argpyrimidine formation on selected arginine residues. Moreover, in
that study we did not investigate hydroimidazolone modiﬁcations. In
the present study, although R103 was modiﬁed to hydroimidazolone,
R21 was not. These observations suggest that the chemical nature of
MGO modiﬁcation and the sites of arginine modiﬁcation depend on
MGO concentration; at low concentrations hydroimidazolone is
the major modiﬁcation and at high concentrations it is both hydro-
imidazolone and argpyrimidine.
The MGO concentration in the human lens has been reported to be
1–2 µM [18,41]. In lens proteins hydroimidazolone is one of the major
chemical modiﬁcations, concentrations as high as 22 nmol/mg have
been reported [22]. Since αA-crystallin is one of the major proteins of
the lens, it is likely that hydroimidazolone formation occurs in this
protein and enhances its chaperone function. MGH1 is the major
isomer among the three isomers of hydroimidazolone. In the human
lens, the reported MGH1 concentrations are 2–14 nmol/mg proteinTable 1
Identiﬁcation of hydroimidazolone modiﬁed sites in MGO-modiﬁed αA-crystallin.
Sequence Mass
(observed)
Mass
(calculated)
12RTLGPFYPSR21 1246.6428 1246.6458
50QSLFRTVLDSGISEVR65 1859.9748 1859.9741
55TVLDSGISEVRSDRDK70 1829.9102 1829.9119
66SDRDKFVIFLDVK78 1634.8682 1634.8668
100HNERQDDHGYISR112 1679.7358 1679.7400
104QDDHGYISREFHR116 1712.7616 1712.7655
113EFHRR117 797.3950 797.3932
117RYRLPSNVDQSALSCSLSADGMLTFCGPK145 3299.5462 3299.5373
118YRLPSNVDQSALSCSLSADGMLTFCGPK145 3143.4322 3143.4362
146IQTGLDATHAERAIPVSR163 1988.0402 1988.0439
158AIPVSREEKPTSAPSS173 1708.8600 1708.8631
Arginine residues in bold are modiﬁed to hydroimidazolone.[22]. We quantiﬁed this product in MGO-modiﬁed αA-crystallin and
found that MGH1 concentration increased with increasing concentra-
tions of MGO (Table 2). The concentrations with 20, 50 and 100 µM
MGO were 1–8 nmol/mg protein, and were within reported values in
the human lens [22]. Thus, we believe that the enhancement in the
chaperone function of αA-crystallin we have observed in this study
with MGO concentrations up to 100 µM could occur in vivo.
3.2. Structural changes in mildly modiﬁed α-crystallin
Far-UV CD spectra showed no changes in the secondary structure
of αA-crystallin after MGO modiﬁcation (Supplemental Fig. S1); the
unmodiﬁed and MGO-modiﬁed proteins showed similar amounts of
α-helix, β-sheet and random coil (∼6%, ∼39% and ∼54%, respective-
ly). The near-UV CD spectrum showed minor alterations in the
tertiary structure in MGO-modiﬁed proteins. The signal intensity for
Phe in the 250–270 nm region was unaffected at up to a 50 µM
concentration of MGO. However, the intensity was slightly decreased
in protein modiﬁed with 100 µM or 500 µM MGO relative to
unmodiﬁed αA-crystallin. There were also minor differences in the
intensity and position of peaks beyond 270 nm (Tyr and Trp) for the
mildly modiﬁed α-crystallin relative to the unmodiﬁed protein. These
data suggest that while the secondary structure is unaffected, the
tertiary structure is slightly altered by mild modiﬁcation with MGO.
Changes in tertiary structure could potentially expose additional
hydrophobic sites on the protein. TNS is a hydrophobic ligand (with a
low ﬂuorescence quantum yield in water) which binds to hydropho-
bic sites on protein molecules. Binding of TNS to hydrophobic sites
dramatically increases its quantum yield [42]. This reagent has been
widely used for probing the surface hydrophobicity of proteins,
including α-crystallin [43,44]. It is evident from the results in Fig. 2
that mild modiﬁcation by MGO causes an increase in the surface
hydrophobicity of αA-crystallin. This increase is dependent on MGO
concentration. The surface hydrophobicity increased by 4% and 30%
with 20 and 500 µM MGO, respectively.
3.3. Chaperone function of mildly modiﬁed α-crystallin
To determine if the increase in surface hydrophobicity resulted in
improvement in the chaperone function of αA-crystallin, we assessedArginine residue
modiﬁed to
hydroimidazolone
Modiﬁed sites observed at MGO
concentration (µM)
20 50 100 500
R12 X X X X
R54 X X X
R65 X X X X
R68 X X X
R103 X X X
R112 X X
R116 X
R117 X X
R119 X
R157 X X X X
R163 X X X X
Fig. 2. Surface hydrophobicity increases in mildly modiﬁed αA-crystallin. Protein
concentration was 0.1 mg/ml and TNS concentration was 100 µM, in 50 mM phosphate
buffer (pH 7.4). The ﬂuorescence spectrum of the samples at 25 °C was recorded
between 350 and 520 nm. The excitation wavelength was 320 nm.
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crystallin, MDH, LDH, CS and insulin. Fig. 3A shows the proﬁle of
aggregation of βL-crystallin in the presence of αA-crystallin. At a 1:40
(w/w) ratio of αA-crystallin to βL-crystallin, we observed nearly 50%
protection with unmodiﬁed αA-crystallin. However, this protection
increased to ∼64 and ∼83% with 100 and 500 µMMGO-modiﬁed αA-
crystallin. At a 1:20 ratio of αA-crystallin to γ-crystallin, we observed
nearly 43% protection against thermal aggregation of γ-crystallin
(Fig. 3B) and it improved to 57%, 84%, 86 and 95% with 20, 50, 100 and
500 µM MGO-modiﬁed αA-crystallin, respectively.
Using MDH as the client protein, at a ratio of nearly 1:1 (w/w) we
observed an enhancement in chaperone function at MGO concentra-
tions >100 µM (Fig. 3C). About a 6% improvement in chaperoneFig. 3. Chaperone function is increased in mildly modiﬁed human αA-crystallin A. Thermal a
ml of γ-crystallin at 65 °C. C. Thermal aggregation of 0.25 mg/ml of MDH at 50 °C. D. Therm
independent measurements.function was seen withαA-crystallin modiﬁed with 100 µMMGO and
this increased to about 34% with αA-crystallin modiﬁed with 500 µM
MGO, in comparison to unmodiﬁed αA-crystallin. With LDH as the
client protein, at a αA-crystallin:LDH ratio of 1:20, a ∼30% enhance-
ment of chaperone function was apparent at a MGO concentration of
100 µM (Fig. 3D). This increased to nearly 45% with 500 µM MGO-
modiﬁed protein in comparison to unmodiﬁed αA-crystallin. Such
improvement in the chaperone function with mildly modiﬁed αA-
crystallin was also seen when insulin and citrate synthase were used
as client proteins (Supplemental Fig. S2).
Together, these data suggest that mild modiﬁcation by MGO is
sufﬁcient to increase the chaperone function, although the increase in
the chaperone function is not uniform across client proteins. There
was no linear relationship between the extent of hydroimidazolone
modiﬁcation and the improvement in the chaperone function. One
explanation could be that since alphaA-crystallin exists as a
poydisperse oligomer with 4–30 subunits that can exchange subunits
between oligomers, it could contribute to the lack of a liner rela-
tionship. Moreover, the lack of a crystal structure for αA-crystallin
makes it difﬁcult to predict how hydroimidazolone modiﬁcation
brings about changes in the chaperone function. Further work with
crystallizable sHsps (such as, Hsp16.9) might shed light on this.
The data also suggest that mild modiﬁcation by MGO increases the
surface hydrophobicity ofαA-crystallin, and thatmay have resulted in
an enhancement of chaperone function. However, it should be
pointed out that change in surface hydrophobicity does not always
correlate with change in chaperone function. Studies have shown that
there is no strict correlation between surface hydrophobicity and
chaperone function in α-crystallin [45]. Furthermore, modiﬁcation of
α-crystallin with high concentrations of MGO (1–10 mM) results in a
dramatic decrease in surface hydrophobicity, while the chaperone
function is still elevated compared to the unmodiﬁed protein [25].ggregation of 0.25 mg/ml of βL-crystallin at 60 °C. B. Thermal aggregation of 0.125 mg/
al aggregation of 0.25 mg/ml of LDH at 60 °C. Each data point is the average of three
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αA-crystallin
Although it is now well established that MGO modiﬁcation
enhances the chaperone function of αA-crystallin, it is not known
whether it would result in the enhancement of its ability to refold
denatured proteins. This was assessed using two human lens proteins.
βL-Crystallin and γ-crystallin in the presence of unmodiﬁed or MGO-
modiﬁed αA-crystallin were denatured by incubating in 8 M urea.
Rapid refolding was done by diluting the denatured proteins in the
refolding buffer. It has been shown that refolding of βL-crystallin and
γ-crystallin is very efﬁcient when αA-crystallin is present during the
denaturation [39]. AlphaA-Crystallin was able to refold βL-crystallin,
as 77% of βL-crystallin was recovered in the soluble form (Fig. 4A).
MGO (20–100 µM) modiﬁcation did not change this property,
although at 500 µM MGO, there was a slight increase in the recovery
(additional 8%). Similarly, αA-crystallin was also able to efﬁciently
refold γ-crystallin with a recovery of 73% in the soluble form (Fig. 4B).
The refolding ability of MGO-modiﬁed αA-crystallin was similar to
unmodiﬁed protein, except in 500 µM MGO-modiﬁed protein, where
a ∼7% increase was observed.
Alpha-crystallin has been shown to prevent thermal inactivation
of several enzymes [46–48]. We tested if this property is affected by
MGO modiﬁcation using CS as the client protein. CS loses its activity
when incubated at 43 °C. AlphaA-Crystallin has the ability to protect
CS from thermal inactivation [49]. MGO-modiﬁed αA-crystallin,
which has the ability to increase protection of CS during thermal
aggregation (Supplemental Fig. 2) and higher surface hydrophobicityFig. 4. The ability of αA-crystallin to refold denatured human lens proteins is
unchanged by mild MGO modiﬁcation. βL-crystallin (A) and γ-crystallin (B) (300 µg
protein each) were denatured in 20 mM sodium phosphate buffer containing 8 M urea
along with 60 µg of native and MGO-modiﬁed αA-crystallin for 5 h at room
temperature. Rapid refolding was done by diluting 50 µl of incubated crystallins with
950 µl of 10 mM phosphate buffer (pH 7.4) containing 100 mM NaCl. The mixture was
incubated for 1 h at room temperature.(Fig. 2), failed to enhance thermal inactivation of CS, and acted in a
fashion similar to unmodiﬁedαA-crystallin, evenwhenmodiﬁedwith
500 µM MGO (Fig. 5A). These data imply that hydrophobic sites thatFig. 5. Inhibition of thermal inactivation of CS and assistance in refolding of chemically
denatured enzymes by MGO-modiﬁed αA-crystallin are similar to unmodiﬁed αA-
crystallin. A. CS (15 µM) was diluted 100-fold in 40 mM HEPES buffer pH 7.4 (to a ﬁnal
volume of 300 µl) in the presence or absence of 30 µM αA-crystallin (native and MGO-
modiﬁed) and incubated at 43 °C. Residual CS activity was measured as described in
Materials and methods. CS diluted as above and kept on ice served as the control. Each
data point is the average of three independent measurements. B. MDH (1 µM) was
denatured in 6 MGdCl for 8 h at 25 °C. Refoldingwas initiated by diluting the denatured
MDH 100-fold in a refolding buffer with or without 30 µM αA-crystallin (native and
MGO-modiﬁed) or BSA. Enzyme concentration during refolding was 10 nM. The activity
of the refolded enzymewas assayed by adding 20 µl of refoldingmixture at various time
intervals to 480 µl of a refolding buffer that contained 0.1 mM NADH and 0.4 mM
oxaloacetate. The decrease in absorbance at 340 nm with time was recorded. MDH
(1 µM) kept on ice served as the control. Each data point is the average of three
independent measurements. C. LDH (1 µM) was denatured in 6 M GdCl for 8 h at 25 °C.
Refoldingwas performed as described for theMDH assay above, with the exception that
0.4 mM of sodium pyruvate was used as the substrate and the assay was performed at
37 °C. The concentration of αA-crystallin (native and MGO-modiﬁed) and BSA was
30 µM. LDH (1 µM) kept on ice served as the control. Each data point is the average of
three independent measurements.
Fig. 6. AlphaA-crystallin–MDH complex loses the ability to refold denatured MDH.
A. Puriﬁcation of αA-crystallin–MDH complex. Catalytically inactive MDH was
incubated with αA-crystallin at 50 °C for 1 h. The complex was centrifuged and the
clear supernatant was chromatographed on Sephacryl S-300. Peak 1 is the αA-
crystallin–MDH complex and peak 2 is free αA-crystallin. MDH from Sigma (cat
#M9004) had the expected molecular weight (monomer=35 kDa), but had a minor
protein at Mr=46 kDa and that protein also bound to αA-crystallin. B. SDS-PAGE of
αA-crystallin–MDH complex. The samples were run on a 15% gel and stained with Bio-
safe Coomassie brilliant blue G 250 (Bio-Rad). Lane 1 is molecular weight markers, lane
2 is MDH alone and lane 3 is αA-crystallin–MDH complex C. MDH refolding assay. The
refolding assay details were similar to those described in the legend for Fig. 5. Each data
point is the average of three independent measurements.
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cause a decrease in inhibition of αA-crystallin-mediated thermal in-
activation of CS.
Alpha-crystallin helps in the in vitro refolding of many enzymes
[50,51]. To determine if MGO modiﬁcation would alter the ability of
αA-crystallin protect to assist in the refolding of denatured en-
zymes, we used denatured LDH and MDH and assayed the level of
reactivation as measure of their refolding to their native states.
LDH andMDHwere inactivated (denatured) by treating themwith
GdHCl. Refolding to the native state was accomplished by diluting
GdHCl with buffer, in the presence or absence of unmodiﬁed or MGO-
modiﬁedαA-crystallin. In the absence ofαA-crystallin, bothMDH and
LDH regained approximately 30% and 20% of the level of activity they
have in the native state, respectively (Fig. 5B and C). In the presence of
unmodiﬁed and MGO-modiﬁed αA-crystallin, both MDH and LDH
regained approximately 60% of the level of activity they have in the
native state. These results suggest that mild modiﬁcation by MGO has
no affect on the protein refolding ability ofαA-crystallin. To determine
if the effects of αA-crystallin on refolding of proteins is speciﬁc, we
used BSA (30 µM) in the place of αA-crystallin in the refolding assays.
BSA did not show any effect in either MDH or LDH refolding assay
(Fig. 5B and C). This suggests that the improvement of the chaperone
function of αA-crystallin by MGO modiﬁcation is speciﬁc.
The above observations are in contrast to a previously published
report [32], where it was found that MGO modiﬁcation diminishes α-
crystallin's ability to refold (activate) denatured enzymes. In that
study, α-crystallin was modiﬁed with high concentrations of MGO
(10 mM). At such high concentrations, α-crystallin is likely to be
extensively crosslinked and therefore might lose its ability to refold
proteins that have been denatured by heat or chaotropic agents.
Further, we determined whether binding of catalytically inactivate
MDH reduces the refolding potential ofαA-crystallin. This experiment
was conducted to test if the binding sites responsible for chaperone
function are the same as those that participate in refolding of
denatured proteins. First, we puriﬁed the αA-crystallin–MDH com-
plex (generated by incubating αA-crystallin with MDH at 50 °C) by
gel ﬁltration (Fig. 6A) and conﬁrmed that the puriﬁed protein had
both αA-crystallin and MDH by SDS-PAGE (Fig. 6B). We then
determined αA-crystallin content in the complex by an ELISA and
used 30 µM αA-crystallin from both free and αA-crystallin–MDH
complex in the MDH refolding assay. The αA-crystallin–MDH com-
plex did not show chaperone function in the MDH assay (data not
shown) and lost the ability to refold denatured MDH (Fig. 6C). These
data demonstrate that the sites responsible for the chaperone and
refolding functions are the same, as the αA-crystallin–MDH complex
completely lost its refolding ability.
Our data show that mild modiﬁcation by MGO exposes additional
hydrophobic sites in αA-crystallin, and that MGO-modiﬁed αA-
crystallin exhibits a refolding ability similar to that of unmodiﬁed αA-
crystallin. To determine if MGO-exposed hydrophobic sites partici-
pate in the chaperone function and refolding of proteins, we ﬁrst
generated a αA-crystallin–TNS complex by incubating αA-crystallin
with TNS and dialyzing this complex against 0.1 M sodium phosphate
buffer (pH 7.4), to remove unbound TNS. At this concentration we
expected TNS to bind most hydrophobic patches in αA-crystallin and
block the chaperone function. As a control, we subjected native αA-
crystallin to similar conditions. As expected, chaperone function was
drastically reduced after TNS binding (Fig. 7A). A portion of both the
native αA-crystallin and the αA-crystallin–TNS complex was then
modiﬁed with 500 µM MGO and their chaperone function was
assessed. Upon modiﬁcation with MGO, the chaperone functions of
αA-crystallin and αA-crystallin–TNS complex increased by 23% and
8%, respectively. This shows that MGO modiﬁcation exposes addi-
tional hydrophobic sites on αA-crystallin.
We then assessed the capacity of MGO-modiﬁed and unmodiﬁed
αA-crystallin–TNS complexes to refold GdHCl denatured MDH. Ourresults show that the αA-crystallin–TNS complex failed to reactivate
denatured MDH, unlike the native αA-crystallin (Fig. 7B). MGO-
modiﬁed αA-crystallin–TNS complex did not show refolding ability
either, suggesting that additional hydrophobic sites exposed upon
MGO modiﬁcation do not participate in the refolding of denatured
proteins. Together these data (Figs. 6 and 7) demonstrate that the
sites responsible for chaperone function and protein refolding are the
same, and MGO modiﬁcation exposes new hydrophobic sites that
interact with client proteins during chaperone function, but these
newly exposed sites do not take part in the refolding of denatured
proteins. Past studies have shown that surface hydrophobicity has a
strong inﬂuence on the ability of α-crystallin to refold denatured
proteins [26,30], and thus our conclusion is in line with these ﬁndings.
However, our study deviates from a previous study that established
that an increase in chaperone function leads to an increase in
refolding ability [31]. However, in that study, metal ions were used to
enhance the chaperone function, not MGO, as in the present study.
There are several possibilities as to why hydroimidazolone modiﬁ-
cation enhances the chaperone function of αA-crystallin. First, hydro-
imidazolone modiﬁcation imparts mild changes in tertiary structure,
which results in the exposure of additional hydrophobic sites that
participate in chaperone function. Second, it could convert the dimeric
substructure to themonomeric substructure of the oligomer, based on a
recently proposed concept [52]. This shift may expose additional sites
with chaperone function. Finally, hydroimidazolone modiﬁcation may
Fig. 7. A. Prior TNS binding signiﬁcantly reduces the chaperone function ofαA-crystallin
but subsequent MGO modiﬁcation improves the function. The ability of the αA-
crystallin–TNS complex (unmodiﬁed andMGO-modiﬁed) to chaperone CSwas assayed.
The reaction conditions are similar to those described in the legend for Fig. 5. B. Prior
TNS binding abolishes the MDH refolding ability of MGO-modiﬁed αA-crystallin. The
assay details were similar to those described in the legend for Fig. 5. Each data point is
the average of three independent measurements.
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function.
Our ﬁndings from this study could have signiﬁcance for cellular
homeostasis. When cells are subjected to stress, a signiﬁcant loss of
enzyme activity and serious damage to other components could occur
and compromise cellular functions. A considerable amount of energy
must be spent to repair such damage to proteins. Renaturation of
denatured proteins, assisted by α-crystallin, could be a mechanism to
thwart cellular damage by stress. Since MGO modiﬁcation enhances
the chaperone function without compromising the refolding ability of
αA-crystallin, we propose that MGO modiﬁcation of αA-crystallin
may be beneﬁcial to cells experiencing stress.Acknowledgements
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